2021/02/26 22:00:00 | |
---|---|
Price | |
224.92 USD | |
Difference | -1.14% (-2.60) |
ISIN | US0311621009 |
Symbol | AMGN |
Exchange | Nasdaq |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 108,216 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 223.08 USD (100) |
Ask (Ask size) | 227.44 USD (100) |
Open | 230.3134 USD |
High | 230.3134 USD |
Low | 223.615 USD |
Close (prev. day) | 227.52 USD |
VWAP | 225.068102 USD |
Volume (pcs) | 3,365,247 |
Trading volume | 757,455,387.45 |
Number of trades | 51,399 |
Last size | 586,027 |
Related Futures | 15 |
Related Options | - |
Date | Headline | Download | |
2021/02/15 |
![]() |
Global Equity Ratings |
![]() |
2021/02/04 |
![]() |
Global Equity Ratings |
![]() |
2021/01/08 |
![]() |
Global Equity Ratings |
![]() |
2020/12/21 |
![]() |
Global Equity Ratings |
![]() |
2020/12/02 |
![]() |
Global Equity Ratings |
![]() |
2021/02/26 22:00:00 | |
---|---|
Price | |
224.92 USD | |
Difference | -1.14% (-2.60) |
ISIN | US0311621009 |
Symbol | AMGN |
Exchange | Nasdaq |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 108,216 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 223.08 USD (100) |
Ask (Ask size) | 227.44 USD (100) |
Open | 230.3134 USD |
High | 230.3134 USD |
Low | 223.615 USD |
Close (prev. day) | 227.52 USD |
VWAP | 225.068102 USD |
Volume (pcs) | 3,365,247 |
Trading volume | 757,455,387.45 |
Number of trades | 51,399 |
Last size | 586,027 |
6m | 1Y | 3Y | |
Perf (%) | -8.34% | +8.15% | +21.88% |
Perf (abs.) | -20.70 | +17.14 | +40.85 |
Beta | 0.83 | 0.77 | 0.80 |
Volatility | 25.31 | 37.74 | 28.42 |
Ø price 5 days | Ø volume 5 days (pcs.) | 230.63 USD (2,637,054) |
Ø price 30 days | Ø volume 30 days (pcs.) | 240.59 USD (2,511,287) |
Ø price 100 days | Ø volume 100 days (pcs.) | 233.52 USD (2,548,380) |
Ø price 250 days | Ø volume 250 days (pcs.) | 233.03 USD (2,807,597) |
YTD High | date | 276.69 USD (2021/01/28) |
YTD Low | date | 223.67 USD (2021/01/04) |
52 Weeks High | date | 276.69 USD (2021/01/28) |
52 Weeks Low | date | 177.05 USD (2020/03/23) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Xetra | 2021/02/26 | 17:35 | 185.44 EUR | 0.25 | 82 |
Vienna Stock Exchange | 2021/02/26 | 17:32 | 185.42 EUR | 0.04 | 11 |
Tradegate | 2021/02/26 | 22:26 | 186.30 EUR | 0.41 | 58 |
Stuttgart | 2021/02/26 | 19:28 | 186.28 EUR | 0.02 | 6 |
SIX Swiss Exchange | 2019/06/27 | 17:35 | 184.90 CHF | 0.00 | 2 |
Nasdaq | 2021/02/26 | 22:00 | 224.92 USD | 757.46 | 51,399 |
Munich | 2021/02/26 | 09:24 | 187.36 EUR | 0.04 | 2 |
London Stock Exchange | 2021/02/26 | 17:35 | 223.975 USD | 0.00 | 4 |
Hong Kong Stock Exchange | 2021/02/11 | 02:20 | 1,761.00 HKD | - | - |
Hanover | 2021/02/26 | 08:04 | 186.54 EUR | 0.00 | 2 |
Hamburg | 2021/02/26 | 16:29 | 184.94 EUR | 0.00 | 2 |
Frankfurt | 2021/02/26 | 16:30 | 185.00 EUR | 0.04 | 4 |
Duesseldorf | 2021/02/26 | 19:31 | 186.10 EUR | 0.00 | 16 |
Borsa Italiana MTF Trading After Hours | 2021/01/12 | 18:12 | 194.86 EUR | 0.00 | 1 |
Borsa Italiana MTF Global Equity Market | 2021/02/26 | 17:35 | 184.92 EUR | 0.02 | 5 |
Berlin | 2021/02/26 | 08:08 | 186.12 EUR | 0.00 | 2 |
AMGEN INC. |
- - |
One Amgen Center Drive - 91320-1799 Thousand Oaks, CA |
Telefon: +1-805-447-1000 |
Fax: +1-805-447-1010 |
E-mail: investor.relations@amgen.com |
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. |
Robert A. Bradway | Chairman of Board of Directors |
Wanda M. Austin | Member of Board of Directors |
Tyler Jacks | Member of Board of Directors |
Ronald D. Sugar | Member of Board of Directors |
Robert A. Eckert | Member of Board of Directors |
R. Sanders Williams | Member of Board of Directors |
Greg C. Garland | Member of Board of Directors |
Fred Hassan | Member of Board of Directors |
Ellen J. Kullman | Member of Board of Directors |
Charles M. Holley Jr. | Member of Board of Directors |
Brian J. Druker | Member of Board of Directors |
Amy E. Miles | Member of Board of Directors |
Robert Bradway | Chairman of Managing Board |
Victoria H. Blatter | Member of Executive Committee |
Tia Bush | Member of Executive Committee |
Susan Sweeney | Member of Executive Committee |
Steven K. Galson | Member of Executive Committee |
Rob Lenz | Member of Executive Committee |
Raymond Deshaies | Member of Executive Committee |
Peter H. Griffith | Member of Executive Committee |
Nancy Grygiel | Member of Executive Committee |
Murdo Gordon | Member of Executive Committee |
Mike Zahigian | Member of Executive Committee |
Mike Nohaile | Member of Executive Committee |
Lori Johnston | Member of Executive Committee |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer